Tonix Pharmaceuticals (TNXP) Projected to Post Quarterly Earnings on Monday

Tonix Pharmaceuticals (NASDAQ:TNXP) is anticipated to announce its earnings results before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($6.23) per share and revenue of $3.35 million for the quarter.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($9.77) EPS for the quarter, missing the consensus estimate of ($6.23) by ($3.54). The business had revenue of $2.58 million during the quarter, compared to analyst estimates of $3.20 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, analysts expect Tonix Pharmaceuticals to post $-1,763 EPS for the current fiscal year and $-542 EPS for the next fiscal year.

Tonix Pharmaceuticals Trading Down 10.6 %

NASDAQ:TNXP opened at $15.64 on Friday. Tonix Pharmaceuticals has a 12-month low of $6.76 and a 12-month high of $672.00. The firm has a market cap of $100.64 million, a PE ratio of 0.00 and a beta of 2.23. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The stock has a fifty day moving average price of $17.50 and a 200 day moving average price of $20.19.

Analysts Set New Price Targets

A number of equities analysts have recently commented on TNXP shares. StockNews.com started coverage on Tonix Pharmaceuticals in a research report on Monday, February 10th. They set a “sell” rating for the company. Noble Financial reiterated an “outperform” rating and set a $70.00 price target on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.